Busulfan, a drug for certain blood cancers, expands the company’s broad oncology portfolio.
Dicyclomine Hydrochloride Injection, an antispasmodic agent, expands Fresenius Kabi’s large and growing generic critical care portfolio.
March 18, 2020
Bad Homburg, Germany
Annual Report 2019
Consolidated Financial Statements and Management Report (IFRS)
January 21, 2020
Frankfurt, Germany
Kepler Cheuvreux 19th German Corporate Conference
January 21 – 22, 2020
Dr. Karl Schneider, a longtime member of the Supervisory Board of Fresenius, has decided to retire from the Supervisory Board of Fresenius Management SE on December 31, 2019. He joined this body in May 2010. From April 1991 until January 2011, Dr. Schneider was a member of the Supervisory Board of Fresenius AG (Fresenius SE starting in July 2007, now Fresenius SE & Co. KGaA), serving as Chairman between 1998 and 2003.
The Supervisory Board and annual general meeting of Fresenius Management SE have named Dr. Schneider as an honorary member of the Supervisory Board of Fresenius Management SE. This appointment recognizes his invaluable, decades-long work on behalf of Fresenius.
An engineer and holder of a doctoral degree in agricultural science, Dr. Schneider was a member of the Management Board of Südzucker AG from 1982 to 1993, and Chief Executive Officer from 1988. He is Deputy Chairman of the Foundation Council of the Else Kröner-Fresenius Foundation. Established in 1988 by Fresenius’ former owner, the late Else Kröner, the foundation is the company’s largest shareholder.
Dr. Gerd Krick, Chairman of the Supervisory Board of Fresenius Management SE and Fresenius SE & Co. KGaA, commented on the departure of his longtime colleague: “Karl Schneider’s work for Fresenius deserves the highest possible recognition and appreciation. He has been closely involved with our company for decades, always giving his full commitment and support to the successful development of Fresenius. On behalf of the Supervisory Board, the Management Board and all the employees, I want to express our great thanks to him. I sincerely wish him all the best, and good health, in the coming years.”
Joining the Supervisory Board of Fresenius Management SE will be Wolfgang Kirsch, who has been elected as a member starting on January 1, 2020. Kirsch joined the Management Board of DZ BANK AG in Frankfurt in 2002 and served as CEO from September 2006 until December 2018. In 2016, under his direction, DZ BANK and WGZ BANK merged into today’s DZ BANK.
“In Wolfgang Kirsch we are welcoming an expert with tremendous experience, especially in financial areas, to our Supervisory Board,” said Dr. Krick. “We are looking forward to working with him.”
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
January 13, 2020
San Francisco, USA
38th Annual J.P. Morgan Healthcare Conference
January 13 – 14, 2020
January 13, 2020
New York, USA
Commerzbank German Investment Seminar
January 13 – 14, 2020